Progyny Cash Flow Statement
PGNY / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Progyny generated $210M in operating cash flow and $192M in free cash flow in FY2025. Free cash flow margin was 14.9% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.62 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | $58.5M | $54.3M | $62.0M | $30.4M | $65.8M | $46.5M | -$8.6M | $661.0K | -$12.5M |
| Depreciation & Amortization | $4.9M | $3.2M | $2.3M | $1.6M | $1.3M | $1.9M | $2.1M | $1.9M | $1.6M |
| Operating Cash Flow | $210.2M | $179.1M | $188.8M | $80.4M | $26.0M | $36.2M | -$1.5M | $2.3M | -$9.5M |
| Capital Expenditures | $18.4M | $5.4M | $3.6M | $3.2M | $2.1M | $1.0M | $3.0M | $579.0K | $612.0K |
| Free Cash Flow | $191.8M | $173.7M | $185.2M | $77.2M | $23.9M | $35.2M | -$4.5M | $1.7M | -$10.1M |
| Share Buybacks | $81.7M | $300.3M | $0 | $0 | - | - | $185.0K | $1.2M | - |
| FCF Margin | 14.9% | 14.9% | 17.0% | 9.8% | 4.8% | 10.2% | - | - | - |